Holdings
Virtus Biotech Clinical Trials Etf
As of Jul 31, 2026, Virtus Biotech Clinical Trials Etf reported 125 positions worth US$44.2M. Largest: First Tracks Biotherapeutics, Inc., Mbx Biosciences, Inc. and Ataibeckley Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| First Tracks Biotherapeutics, Inc. | 17,620 | US$776K | +11,481 | Jul 31, 2026 |
| Mbx Biosciences, Inc. | 8,754 | US$577K | −488 | Jul 31, 2026 |
| Ataibeckley Inc. | 79,289 | US$569K | +14,952 | Jul 31, 2026 |
| Monopar Therapeutics Inc. | 5,200 | US$563K | +1,501 | Jul 31, 2026 |
| Definium Therapeutics, Inc. | 12,558 | US$547K | −9,435 | Jul 31, 2026 |
| Xencor, Inc. | 25,208 | US$509K | +8,501 | Jul 31, 2026 |
| Zenas Biopharma, Inc. | 15,697 | US$494K | +8,898 | Jul 31, 2026 |
| Uniqure N.v. | 11,273 | US$492K | −2,874 | Jul 31, 2026 |
| Apogee Therapeutics, Inc. | 3,519 | US$472K | −61 | Jul 31, 2026 |
| Vor Biopharma Inc. | 21,644 | US$458K | new | Jul 31, 2026 |